AstraZeneca: Lynparza meets primary endpoint
(CercleFinance.com) - On Wednesday AstraZeneca announced that a phase III trial of Lynparza, which it markets with the US pharma giant Merck, has met its primary endpoint in patients with metastatic prostate cancer.
AstraZeneca says that the clinical trial demonstrated a "significant" improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Lynparza is approved in about sixty countries, including those in the European Union for the treatment of ovarian cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
AstraZeneca says that the clinical trial demonstrated a "significant" improvement in radiographic progression-free survival in patients with metastatic castration-resistant prostate cancer.
Lynparza is approved in about sixty countries, including those in the European Union for the treatment of ovarian cancer.
Copyright (c) 2019 CercleFinance.com. All rights reserved.